Link copied to clipboard!

InvAscent invests Rs 1,100 M in Geri Care Health Services

IMT News Desk
IMT News Desk
· 2 min read

Geri Care intends to utilise the funds to expand its services across key cities in Southern India, including Bengaluru, Hyderabad, Kochi and Coimbatore

Healthcare and life sciences-focused private equity investor, InvAscent, through India Life Sciences Fund IV (ILSF IV), has invested Rs 1,100 million in Geri Care Health Services, India’s first integrated senior citizen-focused healthcare services provider.

Founded in 2018 by a leading geriatrician, Dr Lakshmipathy Ramesh, Geri Care offers a comprehensive 360-degree continuum care model for senior citizens, with a network of speciality hospitals, assisted living centres, home care, and clinics.

With over 50 years of combined geriatric practice expertise, Geri Care has become a trusted name in eldercare, serving tens of thousands of elders in South India, particularly in Chennai.

Geri Care intends to utilise the funds to expand its services across key cities in Southern India, including Bengaluru, Hyderabad, Kochi and Coimbatore.

The company is gearing up to launch its newest assisted living facilities in Ulsoor, Bengaluru, and Velachery, Chennai, soon.

“Geri Care is a pioneer in creating an innovative continuum care model, redefining eldercare in India. We are very excited to partner with Dr Ramesh and the team of Geri Care in their growth journey. Our investment aims to support Geri Care’s expansion plans and enhance its capabilities to address the growing needs of the elderly population in India”, said Nithya Govind, MD, InvAscent.

“At Geri Care, we strive to make best-in-class Geriatric Care accessible to our senior community and their families and to enhance the quality of their life, promote independence, well-being and dignity. We are excited to partner with InvAscent to further our mission of providing holistic and compassionate care to the elderly. This investment and partnership will enable us to expand our services and reach more seniors in need of specialized healthcare”, said Dr Lakshmipathy Ramesh, Founder and MD, Geri Care.

Veda Corporate Advisors served as the exclusive financial advisor to Geri Care for this transaction.

Read Next

Granules India posts Rs 13,879 million revenue from operations at Q3FY26
Finance
January 28, 2026

Granules India posts Rs 13,879 million revenue from operations at Q3FY26

Net debt stood at Rs 10,151 million and net debt to EBITDA at 0.91x Granules India has announced its financial results for the quarter ended December 31, 2025. Revenue from Operations of Q3FY26 stood at Rs 13,879 million, a growth of 22 per cent YoY driven by Finished Dosages (FD) segment in North America and […]
Article by: IMT News Desk
OneSource Pharma’s revenue down at Rs 2,903 million in Q3FY26
Finance
January 28, 2026

OneSource Pharma’s revenue down at Rs 2,903 million in Q3FY26

Impacted by delayed semaglutide approvals in Canada OneSource has posted the Q3FY26 results. Revenues were at Rs 2,903 million, down 26 per cent YoY, impacted by delayed semaglutide approvals in Canada. The EBITDA was at Rs 173 million, down 88 per cent YoY, due to lower revenue in the quarter and largely fixed cost base. […]
Article by: IMT News Desk
Syngene International’s Q3 revenue from operations dip 3% year-on-year to Rs 917 Cr
Finance
January 27, 2026

Syngene International’s Q3 revenue from operations dip 3% year-on-year to Rs 917 Cr

Reported revenue dips to Rs 932 crore in the same quarter Syngene International announced financial results for the third quarter of FY26. Peter Bains, Managing Director and CEO, Syngene International, said, “Our Q3 performance reflects the ongoing impact related to a single product from one of our large-molecule biologics clients. Outside of this factor, the […]
Article by: IMT News Desk
Sigachi Industries aims to increase revenue potential by Rs 250 cr commencing from Q427
Finance
January 27, 2026

Sigachi Industries aims to increase revenue potential by Rs 250 cr commencing from Q427

Sigachi’s entry into CF APIs positions the company in a structurally strong and innovation-led therapeutic segment with long-term demand visibility Sigachi Industries announced a significant milestone in its research and development pipeline with the successful advancement of a new Cystic Fibrosis (CF) Active Pharmaceutical Ingredients (APIs) combination comprising Vanzacaftor, Tezacaftor, and Deutivacaftor. The development marks […]
Article by: IMT News Desk